Trade Landos Biopharma, Inc. - LABP CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.27 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Landos Biopharma Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 21.3 |
Open* | 21.35 |
1-Year Change* | 5518.42% |
Day's Range* | 21.3 - 21.65 |
52 wk Range | 0.21-1.37 |
Average Volume (10 days) | 72.96K |
Average Volume (3 months) | 3.98M |
Market Cap | 9.67M |
P/E Ratio | -100.00K |
Shares Outstanding | 31.17M |
Revenue | N/A |
EPS | -0.70 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Aug 9, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2024 | 21.30 | 0.00 | 0.00% | 21.30 | 21.54 | 21.30 |
Mar 26, 2024 | 21.35 | -0.15 | -0.70% | 21.50 | 21.58 | 21.30 |
Mar 25, 2024 | 21.35 | -0.10 | -0.47% | 21.45 | 21.75 | 20.96 |
Mar 22, 2024 | 7.76 | 0.09 | 1.17% | 7.67 | 7.93 | 7.42 |
Mar 21, 2024 | 7.52 | 0.36 | 5.03% | 7.16 | 7.63 | 6.92 |
Mar 20, 2024 | 6.99 | -0.16 | -2.24% | 7.15 | 7.15 | 6.87 |
Mar 19, 2024 | 7.07 | 0.40 | 6.00% | 6.67 | 7.07 | 6.38 |
Mar 18, 2024 | 6.44 | 0.09 | 1.42% | 6.35 | 6.49 | 6.35 |
Mar 15, 2024 | 6.53 | 0.22 | 3.49% | 6.31 | 6.54 | 6.22 |
Mar 14, 2024 | 6.25 | -0.18 | -2.80% | 6.43 | 6.49 | 6.19 |
Mar 13, 2024 | 6.38 | 0.09 | 1.43% | 6.29 | 6.53 | 6.28 |
Mar 12, 2024 | 6.31 | 0.27 | 4.47% | 6.04 | 6.31 | 6.04 |
Mar 11, 2024 | 6.19 | -0.06 | -0.96% | 6.25 | 6.29 | 5.94 |
Mar 8, 2024 | 6.10 | -0.28 | -4.39% | 6.38 | 6.38 | 6.01 |
Mar 7, 2024 | 6.29 | -0.20 | -3.08% | 6.49 | 6.49 | 6.11 |
Mar 6, 2024 | 6.55 | 0.03 | 0.46% | 6.52 | 6.61 | 6.52 |
Mar 5, 2024 | 6.50 | 0.10 | 1.56% | 6.40 | 6.57 | 6.39 |
Mar 4, 2024 | 6.51 | 0.28 | 4.49% | 6.23 | 6.51 | 6.23 |
Mar 1, 2024 | 6.27 | -0.04 | -0.63% | 6.31 | 6.31 | 6.23 |
Feb 29, 2024 | 6.23 | 0.02 | 0.32% | 6.21 | 6.48 | 6.17 |
Landos Biopharma, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Friday, May 10, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q1 2024 Landos Biopharma Inc Earnings Release Q1 2024 Landos Biopharma Inc Earnings ReleaseForecast -Previous - |
Wednesday, May 22, 2024 | ||
Time (UTC) 13:00 | Country US
| Event Landos Biopharma Inc Annual Shareholders Meeting Landos Biopharma Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 18 | 0 | 0 | 0 |
Total Operating Expense | 40.561 | 56.816 | 30.676 | 13.29 | 7.939 |
Selling/General/Admin. Expenses, Total | 14.581 | 15.252 | 5.338 | 1.478 | 1.136 |
Research & Development | 25.68 | 41.564 | 25.338 | 11.812 | 6.803 |
Operating Income | -40.561 | -38.816 | -30.676 | -13.29 | -7.939 |
Interest Income (Expense), Net Non-Operating | 0.026 | -0.018 | 0.077 | -0.337 | -0.11 |
Other, Net | 1.259 | 0.412 | 0.455 | 0.16 | 2.005 |
Net Income Before Taxes | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Net Income After Taxes | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Net Income Before Extra. Items | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Net Income | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Income Available to Common Excl. Extra. Items | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Income Available to Common Incl. Extra. Items | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Diluted Net Income | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Diluted Weighted Average Shares | 40.2549 | 37.5585 | 40.1176 | 39.1632 | 39.1632 |
Diluted EPS Excluding Extraordinary Items | -0.97568 | -1.02299 | -0.75139 | -0.34387 | -0.15433 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | -0.96823 | -1.02299 | -0.75139 | -0.34387 | -0.15433 |
Revenue | 0 | 18 | |||
Unusual Expense (Income) | 0.3 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 6.479 | 6.513 | 7.829 | 11.266 | 14.953 |
Selling/General/Admin. Expenses, Total | 3.153 | 3.099 | 2.967 | 4.662 | 3.853 |
Research & Development | 3.326 | 3.414 | 4.862 | 6.604 | 10.8 |
Operating Income | -6.479 | -6.513 | -7.829 | -11.266 | -14.953 |
Interest Income (Expense), Net Non-Operating | -0.004 | 0 | 0 | 0.025 | 0.001 |
Other, Net | 0.449 | 1.281 | -0.067 | -0.043 | 0.088 |
Net Income Before Taxes | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 |
Net Income After Taxes | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 |
Net Income Before Extra. Items | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 |
Net Income | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 |
Income Available to Common Excl. Extra. Items | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 |
Income Available to Common Incl. Extra. Items | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 |
Diluted Net Income | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 |
Diluted Weighted Average Shares | 64.8423 | 40.2549 | 40.2549 | 40.2549 | 40.2549 |
Diluted EPS Excluding Extraordinary Items | -0.09306 | -0.12997 | -0.19615 | -0.28031 | -0.36925 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.09306 | -0.12997 | -0.19615 | -0.28031 | -0.36179 |
Revenue | 0 | 0 | 0 | ||
Unusual Expense (Income) | 0 | 0 | 0 | 0.3 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 45.253 | 92.146 | 29.888 | 50.11 | 2.492 |
Cash and Short Term Investments | 44.402 | 90.88 | 28.134 | 49.965 | 0.359 |
Cash & Equivalents | 36.64 | 8.305 | 2.416 | 9.808 | 0.359 |
Short Term Investments | 7.762 | 82.575 | 25.718 | 40.157 | 0 |
Total Receivables, Net | 0.154 | 0.001 | 2.092 | ||
Prepaid Expenses | 0.851 | 1.266 | 0.202 | 0.144 | 0.041 |
Total Assets | 45.253 | 92.879 | 30.332 | 50.48 | 2.796 |
Property/Plant/Equipment, Total - Net | 0 | 0.707 | 0.444 | 0.359 | 0.304 |
Property/Plant/Equipment, Total - Gross | 0.166 | 1.248 | 0.793 | 0.571 | 0.413 |
Accumulated Depreciation, Total | -0.166 | -0.541 | -0.349 | -0.212 | -0.109 |
Other Long Term Assets, Total | 0 | 0.026 | 0 | 0.011 | 0 |
Total Current Liabilities | 6.122 | 16.611 | 11.034 | 3.026 | 1.796 |
Accounts Payable | 3.435 | 12.908 | 8.606 | 2.048 | 1.692 |
Accrued Expenses | 2.687 | 3.703 | 1.939 | 0.978 | 0.104 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6.122 | 16.611 | 11.31 | 3.026 | 1.796 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 39.131 | 76.268 | 19.022 | 47.454 | 1 |
Redeemable Preferred Stock | 0 | 0 | 73.037 | 73.037 | 0.032 |
Common Stock | 0.403 | 0.403 | 0.071 | 0.063 | 0.059 |
Additional Paid-In Capital | 172.212 | 170.241 | 1.633 | 0.016 | 10.044 |
Retained Earnings (Accumulated Deficit) | -133.427 | -94.151 | -55.729 | -25.585 | -9.135 |
Other Equity, Total | -0.057 | -0.225 | 0.01 | -0.077 | 0 |
Total Liabilities & Shareholders’ Equity | 45.253 | 92.879 | 30.332 | 50.48 | 2.796 |
Total Common Shares Outstanding | 40.2549 | 40.2549 | 40.1176 | 39.1632 | 39.1632 |
Other Current Assets, Total | 0 | 1.398 | |||
Other Current Liabilities, Total | 0 | 0.489 | |||
Other Liabilities, Total | 0 | 0.276 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 51.184 | 45.253 | 49.488 | 58.038 | 77.359 |
Cash and Short Term Investments | 50.006 | 44.402 | 47.991 | 55.751 | 73.796 |
Cash & Equivalents | 45.244 | 36.64 | 28.88 | 19.241 | 11.288 |
Short Term Investments | 4.762 | 7.762 | 19.111 | 36.51 | 62.508 |
Total Receivables, Net | |||||
Prepaid Expenses | 1.178 | 0.851 | 1.497 | 2.287 | 3.563 |
Other Current Assets, Total | |||||
Total Assets | 51.184 | 45.253 | 49.488 | 58.038 | 77.61 |
Property/Plant/Equipment, Total - Net | 0 | 0 | 0 | 0.251 | |
Total Current Liabilities | 4.16 | 6.122 | 5.475 | 6.51 | 15.507 |
Accounts Payable | 2.298 | 3.435 | 3.204 | 4.711 | 9.803 |
Accrued Expenses | 1.862 | 2.687 | 2.271 | 1.799 | 5.704 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | |||||
Total Liabilities | 4.16 | 6.122 | 5.475 | 6.51 | 15.507 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | |||||
Total Equity | 47.024 | 39.131 | 44.013 | 51.528 | 62.103 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
Common Stock | 0.312 | 0.403 | 0.403 | 0.403 | 0.403 |
Additional Paid-In Capital | 186.094 | 172.212 | 172.016 | 171.816 | 171.182 |
Retained Earnings (Accumulated Deficit) | -139.461 | -133.427 | -128.195 | -120.299 | -109.015 |
Other Equity, Total | 0.079 | -0.057 | -0.211 | -0.392 | -0.467 |
Total Liabilities & Shareholders’ Equity | 51.184 | 45.253 | 49.488 | 58.038 | 77.61 |
Total Common Shares Outstanding | 31.1684 | 40.2549 | 40.2549 | 40.2549 | 40.2549 |
Other Long Term Assets, Total | 0 | 0 | 0 | ||
Property/Plant/Equipment, Total - Gross | 0.166 | 0.575 | 1.041 | 1.125 | |
Accumulated Depreciation, Total | -0.166 | -0.575 | -1.041 | -0.874 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Cash From Operating Activities | -45.771 | -27.061 | -22.962 | -9.874 | -6.896 |
Cash From Operating Activities | 0.577 | 0.196 | 0.137 | 0.103 | 0.08 |
Non-Cash Items | 3.002 | 5.274 | 1.174 | 0.213 | 0.369 |
Cash Interest Paid | 0 | 0.027 | 0.004 | ||
Changes in Working Capital | -10.074 | 5.891 | 5.871 | 3.277 | -1.301 |
Cash From Investing Activities | 74.06 | -58.706 | 14.131 | -40.325 | -0.043 |
Capital Expenditures | -0.007 | -0.44 | -0.181 | -0.158 | -0.043 |
Other Investing Cash Flow Items, Total | 74.067 | -58.266 | 14.312 | -40.167 | 0 |
Cash From Financing Activities | 0 | 91.607 | 1.518 | 59.648 | 5 |
Issuance (Retirement) of Stock, Net | 0 | 93.514 | 1.518 | 51.668 | 5 |
Issuance (Retirement) of Debt, Net | 0 | 7.98 | 0 | ||
Net Change in Cash | 28.335 | 5.889 | -7.392 | 9.449 | -1.939 |
Foreign Exchange Effects | 0.046 | 0.049 | -0.079 | ||
Financing Cash Flow Items | 0 | -1.907 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -6.034 | -39.276 | -34.044 | -26.148 | -14.864 |
Cash From Operating Activities | -8.17 | -45.771 | -42.072 | -34.499 | -16.502 |
Cash From Operating Activities | 0 | 0.577 | 0.577 | 0.577 | 0.353 |
Non-Cash Items | 0.256 | 3.002 | 2.82 | 2.238 | 1.381 |
Changes in Working Capital | -2.392 | -10.074 | -11.425 | -11.166 | -3.372 |
Cash From Investing Activities | 3.104 | 74.06 | 62.589 | 45.377 | 19.506 |
Capital Expenditures | 0 | -0.007 | -0.007 | -0.007 | -0.007 |
Other Investing Cash Flow Items, Total | 3.104 | 74.067 | 62.596 | 45.384 | 19.513 |
Cash From Financing Activities | 13.666 | 0 | 0 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 13.666 | 0 | 0 | 0 | 0 |
Net Change in Cash | 8.604 | 28.335 | 20.575 | 10.936 | 2.983 |
Foreign Exchange Effects | 0.004 | 0.046 | 0.058 | 0.058 | -0.021 |
Financing Cash Flow Items | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Landos Biopharma, Inc. Company profile
About Landos Biopharma Inc
Landos Biopharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The Company through its artificial intelligence (AI)-based precision medicine platform, LANCE platform, identifies therapeutic targets based on predictions of immunometabolic function and create therapeutic candidates to engage those targets in areas of unmet medical need. Its platform discovers small molecule therapeutics for patients with autoimmune diseases that targets mechanisms of action, including LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. It identifies novel immunometabolic targets and product candidates across indications, such as ulcerative colitis (UC), Crohn’s disease (CD), eosinophilic esophagitis (EoE), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its Omilancor is an oral, gut restricted LANCL2 agonist in development for the treatment of UC, CD and EoE.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Landos Biopharma Inc revenues increased from $0K to $18M. Net loss decreased 3% to $18.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.48 to -$0.57.
Industry: | Biotechnology & Medical Research (NEC) |
1800 Kraft Drive, Suite 216
24060
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com